Land: Irland
Sprache: Englisch
Quelle: HPRA (Health Products Regulatory Authority)
RANITIDINE HYDROCHLORIDE
PCO Manufacturing
300mg Milligram
Tablets
1998-11-27
PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Zantac 300 mg Film-coated Tablets. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 300 mg ranitidine (as hydrochloride). _For excipients, see 6.1._ 3 PHARMACEUTICAL FORM Film-coated Tablet. White, capsule-shaped tablets with ‘GX EC3’ on one side and plain on the other side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS In the treatment of duodenal ulcer and benign gastric ulcer including that associated with non-steriodal anti- inflammatory agents. Prevention of non-steriodal anti-inflammatory drug (including aspirin) associated duodenal ulcers, especially in patients with a history of peptic ulcer disease. ZANTAC tablets are also indicated for treatment of post-operative ulcer, reflux oesophagitis, Zollinger-Ellison syndrome and other conditions where reduction of gastric acid secretion is likely to be beneficial. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _ADULTS: _the usual initial dosage is 150mg bd or 300mg nocte. This may be increased to 300mg twice daily without an increased incidence of unwanted effects. Subsequently a maintenance dose of 150mg nocte may be used. Smoking is associated with a higher rate of ulcer relapse, and such patients should be advised to stop smoking. In those who fail to comply with such advice, a dose of 300mg at night proves additional therapeutic benefit over the standard dose. In most cases of duodenal ulcer, benign gastric ulcer and post operative ulcer, healing occurs within 4 weeks. Healing usually occurs after a further 4 weeks in those not fully healed after the initial 4 weeks. In ulcers following non- steroidal anti-inflammatory drug therapy, 8-12 weeks treatment may be necessary. For the prevention of non-steroidal anti-inflammatory drug Lesen Sie das vollständige Dokument